South Korea's ADEL signs up to $1.04 billion Alzheimer's drug development deal with Sanofi

South Korea's ADEL signs up to $1.04 billion Alzheimer's drug development deal with Sanofi | Global Banking & Finance Review | GBAF

Editorial & Advertiser disclosure

Global Banking and Finance Review is an online platform offering news, analysis, and opinion on the latest trends, developments, and innovations in the banking and finance industry worldwide. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.

Home > Headlines > South Korea's ADEL signs up to $1.04 billion Alzheimer's drug development deal with Sanofi

Headlines

South Korea's ADEL signs up to $1.04 billion Alzheimer's drug development deal with Sanofi

Published by Global Banking and Finance Review

Posted on December 16, 2025

Featured image for article about Headlines

Tags:partnership innovation Biotech

Dec ‌16 (Reuters) - South Korea-based ADEL said late ‍on ‌Monday that it has entered a $1.04 billion partnership ⁠with French ‌drugmaker Sanofi to develop and sell the biotech company's experimental Alzheimer's disease treatment.

Under the terms ⁠of the agreement, ADEL will receive an upfront payment of $80 million, with additional milestone ‌payments tied to ⁠development progress and commercial performance, as well as royalties on future sales.

Sanofi signed a separate deal with private biotech Dren Bio worth up to $1.7 billion on Monday to develop autoimmune disease therapies.

ADEL's drug candidate, ‍ADEL-Y01, is an antibody therapy designed to block harmful forms of a protein linked to Alzheimer's disease. It is currently in early-stage human trials in the United States.

"ADEL's innovative ⁠approach to targeting tau acetylation offers a promising and differentiated mechanism for addressing the underlying causes of Alzheimer's disease," said Erik Wallstroem, global head, Multiple Sclerosis, Neurology and ‌Gene Therapy Development at Sanofi.

(Reporting by Sahil Pandey in Bengaluru; Editing by Sherry Jacob-Phillips)

Frequently Asked Questions about South Korea's ADEL signs up to $1.04 billion Alzheimer's drug development deal with Sanofi

1What is Alzheimer's disease?

Alzheimer's disease is a progressive neurological disorder that causes brain cells to degenerate and die, leading to memory loss, cognitive decline, and changes in behavior.

2What is a partnership in business?

A partnership in business refers to a formal arrangement where two or more parties agree to manage and operate a business together, sharing profits and responsibilities.

3What are milestone payments?

Milestone payments are payments made upon the completion of specific stages or achievements in a project, often used in contracts to ensure progress.

4What are royalties?

Royalties are payments made to the owner of a property or intellectual property for the right to use that property, often calculated as a percentage of sales or profits.